Whalesbook
Profit Surge Boosts Apollo Hospitals' Q4 Performance
Apollo Hospitals Enterprise Ltd. reported a strong financial performance for the fourth quarter of fiscal year 2026, with net profit climbing 36% year-on-year to ₹529 crore. Consolidated revenue for the period ending March 31, 2026, rose 18% to ₹6,605 crore. This growth was broad-based, benefiting from contributions across its hospital, diagnostics, and digital health segments. For the full fiscal year 2026, Apollo Hospitals achieved consolidated revenue of ₹25,229 crore, a 16% increase from the previous year, while net profit grew 34% to ₹1,942 crore.
Fertility Services Merge with Cloudnine
In a significant strategic move, Apollo Hospitals' board has approved the merger of its fertility services, Apollo Cradle & Fertility, with Cloudnine. This proposed combination, pending approval from the Competition Commission of India, aims to create a leading entity in the maternity and fertility care market. The transaction is valued at ₹1,550 crore and includes a cash component along with a 9.9% stake in the merged entity for Apollo Hospitals. This consolidation reflects a wider trend in the Indian healthcare industry, where companies are increasingly merging or acquiring specialized units to expand market reach and operational efficiency.
Operational Wins and Digital Health Growth
Management highlighted improved operational performance across its business segments. The EBITDA margin for its established hospital units increased to 25.5% in Q4FY26, up from 24.4% in the same quarter last year. The company also reported reduced cash burn and increased efficiency in its online business operations. Apollo HealthCo, its digital health division, saw revenue grow by 19% in FY26 and achieved a net profit of ₹324 crore. The retail healthcare and diagnostics unit, Apollo Health and Lifestyle, also experienced a 20% revenue increase while successfully narrowing its losses. A demerger of its pharmacy and digital health businesses for a separate listing is planned by Q4 FY27.
Market Valuation and Sector Outlook
Apollo Hospitals currently trades at a premium valuation, with a P/E ratio of approximately 64.49, exceeding its sector peers. Its P/B ratio stands at 12.03. Despite these high valuations, analysts largely maintain a positive outlook, with a consensus 'Strong Buy' rating and an average 12-month price target suggesting potential upside. The Indian healthcare sector is projected to grow significantly, reaching over $610 billion by 2026, driven by factors such as rising incomes, better insurance coverage, and an increasing prevalence of lifestyle diseases. The sector is also evolving towards 'intelligent healthcare' and platform-based solutions.
Valuation Concerns and Integration Challenges
While Apollo Hospitals demonstrates strong growth and a positive sector outlook, its high valuation remains a point of caution. The stock's P/E ratio of 64.49 is notably higher than the industry average. Sustained profitability could face pressure from growing competition and the substantial investments required for its digital health initiatives and infrastructure expansion. The company's enterprise value to sales ratio is also among the highest globally. The successful integration of the fertility units and the realization of expected synergies will be crucial for the planned merger's success. Apollo Hospitals currently offers a small dividend, indicating a primary focus on reinvesting earnings for growth.